Lynparza (Lipzo) anti-cancer targeted drug

Olaparib (Olaparib), as a revolutionary targeted drug, has demonstrated its extraordinary strength on the anti-cancer front. It achieves significant anti-tumor effects by precisely interfering with several core biological processes within cancer cells.

First, olaparib has excellent cell cycle regulation capabilities. It can subtly interfere with specific proteins in the cell cycle, thereby effectively curbing the abnormal division and proliferation of cancer cells, which plays a vital role in inhibiting tumor growth.

More than that, Lynparza also plays a key rolein the DNA damage repair mechanism. It can effectively block the DNA repair channels of cancer cells, causing DNA damage to accumulate, ultimately inhibiting the growth of cancer cells and even promoting apoptosis.

Lynparza can also target cancers caused by mutations in specific oncogenic driver genes. By reducing the risk of tumors caused by these overactivated genes, olaparib fights cancer cells at the genetic level.

It is worth mentioning that olaparib has also achieved remarkable results in anti-tumor angiogenesis. It can reduce the activity of pro-angiogenic factors, thereby indirectly inhibiting the formation of blood vessels around the tumor, cutting off the tumor's nutritional source and blood transfer path, thereby effectively controlling the spread and metastasis of the tumor.

These outstanding effects of olaparib make it shine in the treatment of various cancers, especially in the treatment of ovarian cancer. Its excellent efficacy and safety have won the trust of many patients. However, it needs to be emphasized that olaparib is a prescription drug and must be purchased and used under the guidance of a doctor to ensure patient medication safety and therapeutic effect.

Now, Lynparza has been launched in my country and has been included in the medical insurance system, bringing good news to more patients. In my country, the specifications of Lynparza's original tablets are 150mg*56 tablets, and the price after reimbursement by medical insurance is about 4,500 yuan, but the specific price may vary depending on regional hospitals. At the same time, overseas markets also provide a variety of generic options for olaparib, including capsules and tablets, which are relatively more affordable and provide patients with more treatment options.